Today: 21 May 2026
Uranium Energy stock jumps 12% as uranium miners rally to start 2026 — what’s next for UEC
4 January 2026
1 min read

Uranium Energy stock jumps 12% as uranium miners rally to start 2026 — what’s next for UEC

New York, Jan 3, 2026, 19:20 ET — Market closed

  • Uranium Energy Corp. shares rose 12.2% on Friday, closing at $13.11.
  • Uranium miners moved higher across the board, with Energy Fuels and Denison Mines also posting double-digit gains.
  • Investors are watching uranium prices, permitting milestones and next week’s U.S. data for the next move.

Uranium Energy Corp. shares jumped 12.2% on Friday to close at $13.11, kicking off 2026 with a sharp gain as uranium miners rallied. The NYSE American-listed stock traded between $11.90 and $13.24 on volume of about 9.2 million shares.

The buying spilled across uranium miners and related funds, pointing to broad positioning rather than a single-stock move. The Sprott Uranium Miners ETF (URNM) rose 7.4% by net asset value on Friday.

Spot uranium was little changed at about $81.65 a pound on Jan. 2, but it was still up about 7% over the past month, Trading Economics data showed.

Peers moved in step: Energy Fuels gained about 14.9%, Denison Mines rose roughly 13.2% and Cameco advanced 7.7% in U.S. trading on Friday.

Denison helped set the tone after it said it was ready to make a final investment decision and begin building its proposed Phoenix in‑situ recovery uranium mine, pending final regulatory approvals. “Denison stands ready to make a final investment decision and commence construction of the Phoenix ISR mine,” President and CEO David Cates said. PR Newswire

An in‑situ recovery mine, or ISR, extracts uranium by circulating a solution through underground ore and pumping the uranium-bearing fluid back to the surface for processing. A final investment decision is a formal sign-off to start construction and commit capital.

Uranium Energy, based in the United States, has been advancing ISR projects in Texas and Wyoming and also holds conventional uranium projects in Canada, according to Reuters company information. The company also holds physical uranium inventory and stakes in uranium-related investments.

Traders often treat permitting milestones and capital-spending signals as markers of how quickly new supply can reach the market. Friday’s rally suggested investors were again willing to pay up for that pipeline, even with uranium prices steady.

Investors will watch whether the move holds when markets reopen, with uranium equities often amplifying small shifts in the commodity and risk appetite. Flows into sector ETFs and any fresh company updates in the group are likely to set the early tone.

Before the next session on Monday, focus returns to U.S. data and rates after thin holiday trading, with the monthly jobs report due Jan. 9 and consumer-price data scheduled for Jan. 13, while quarterly earnings season begins to ramp up, a Reuters Week Ahead report said.

On the company calendar, Uranium Energy is expected to report results around March 10, according to Zacks. Traders will look for updates on production plans, contracting and cash deployment after the year-end repositioning.

Technically, Friday’s $13.24 high is the near-term level bulls will want to retest, while a slip back below $13 would put the rally’s follow-through in question.

Stock Market Today

  • Nvidia's Earnings Surge Fuels Massive Buybacks and AI Investments
    May 21, 2026, 5:32 AM EDT. Nvidia's latest earnings showcased an 85% revenue jump to $81.6 billion, driven by a booming AI sector. The chipmaker returned about $20 billion to shareholders through buybacks and raised its quarterly dividend, while authorizing an additional $80 billion in buybacks. It also invested heavily in AI-related firms, holding nearly $74 billion in equity stakes across public and private companies. Data center sales, key to AI growth, soared 92% to $75.2 billion, with free cash flow increasing 86% to $48.6 billion. Nvidia's cash flow now funds both shareholder returns and expanding AI investments, underscoring the scale of its AI-driven business model.

Latest articles

Rocket Lab Shares Slide Premarket On $3 Billion Sale Plan During SpaceX IPO Week

Rocket Lab Shares Slide Premarket On $3 Billion Sale Plan During SpaceX IPO Week

21 May 2026
Rocket Lab filed to sell up to $3 billion in common stock, sending shares down to $126.75 in premarket trading from Wednesday’s $134.28 close. The move comes as SpaceX filed for a public IPO, raising valuation pressure across the sector. Rocket Lab’s year-to-date gain stood near 92% before the late-Wednesday announcement. The company reported $200.3 million in Q1 revenue and a $2.2 billion backlog.
Snowflake Heads Toward $205 BofA Level Before Earnings Next Week

Snowflake Heads Toward $205 BofA Level Before Earnings Next Week

21 May 2026
Snowflake shares fell 1.5% to $166.97 in early Thursday trading after Bank of America raised its price target to $205 and reiterated a Buy rating ahead of fiscal Q1 results due May 27. RBC cut its target earlier this week, highlighting ongoing competition in data and AI. Snowflake previously guided for Q1 product revenue of $1.262–$1.267 billion, up 27% year-over-year.
Arm jumps in premarket on AI chip hopes

Arm jumps in premarket on AI chip hopes

21 May 2026
Arm Holdings shares closed Wednesday at $256.73, up 15.05%, after Bernstein’s David Dai initiated coverage with an outperform rating and a $300 target, citing rising demand for server CPUs driven by agentic AI. The stock touched $259.44 during regular trading. U.S. markets were open; May 21 is not a listed exchange holiday. Arm’s AGI CPU has over $2 billion in expected demand for fiscal 2027 and 2028.
Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next
Previous Story

Bloom Energy stock jumps 14% to start 2026 as fuel-cell names rebound — what investors watch next

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus
Next Story

Spyre Therapeutics stock slides 6.6% after New Year session; $30 level and 2026 trial data in focus

Go toTop